- Cuprina Holdings (CUPR, Financial) announces a $12 million IPO at $4.00 per share.
- The IPO includes 3 million shares with an option for underwriters to purchase an additional 450,000 shares.
- Shares are set to commence trading on NASDAQ under the symbol 'CUPR' on April 10, 2025.
Cuprina Holdings (CUPR), a biomedical and biotechnology company specializing in chronic wound management and cosmeceuticals, has officially priced its Initial Public Offering (IPO). The company is offering 3,000,000 Class A Ordinary Shares at a price of $4.00 per share. A 45-day over-allotment option allows underwriters to purchase up to an additional 450,000 shares, potentially increasing the total gross proceeds to $13.80 million, assuming full exercise of the option.
Trading for Cuprina Holdings is set to begin on NASDAQ under the ticker symbol 'CUPR' on April 10, 2025. The offering is expected to close on April 11, 2025, subject to customary closing conditions. R. F. Lafferty & Co. is the sole book-running manager for this offering, providing crucial guidance for the transaction.
The IPO enables Cuprina Holdings to gain access to public capital markets, with an aim to support their operations in addressing growing healthcare needs related to aging populations and increasing chronic disease prevalence. The company’s focus lies in the development and commercialization of medical products for chronic wounds and health and beauty cosmeceuticals.
This public listing not only enhances Cuprina Holdings' market visibility but also positions the company strategically for future capital opportunities through additional offerings, contingent on the success of their initial commercialization efforts.
